Recent Updates — ANGO

AngioDynamics reported fiscal first quarter 2027 net sales of $80.9 million, a 6.9% increase year-over-year, driven by a 13.2% rise in Med Tech segment revenue to $39.9 million and flat Med Device sales at $41.0 million. The company posted an adjusted EBITDA of $5.0 million and reaffirmed its full-year fiscal 2027 net sales guidance of $336.0M to $341.0M. Concurrently, the board appointed Eric Honroth as President and Chief Executive Officer, effective November 2, 2026, succeeding retiring CEO Jim Clemmer. AngioDynamics is a medical technology company focused on vascular health solutions and cancer treatment devices.

AngioDynamics appointed Eric Honroth as President and Chief Executive Officer, effective November 2, 2026. Mr. Honroth receives a $735,000 base salary, a $1.49 million initial equity grant, and a $350,000 sign-on bonus. Outgoing CEO James Clemmer retires from the board on the same date but enters a consulting agreement for an additional year at $360,000 annually. The company also granted retention agreements to its executive leadership team to accelerate equity vesting upon successful transition completion. AngioDynamics is a medical technology company focused on vascular health and cancer treatment solutions.

AngioDynamics, Inc. issued a press release on July 14, 2026, announcing its financial results for the fiscal fourth quarter and full year ended May 31, 2026. The filing includes presentation slides discussing the company's performance and business strategy. AngioDynamics, Inc. is a medical technology company that develops and manufactures medical devices and related products for a variety of medical specialties.